A further Ctsl knockout study using the MycERTAM-BclxL pancreatic neuroendocrine cancer revealed an impairment in tumor progression toward the latest stages, an increase in tumor cell death, and elevated expression of autophagy markers, together with defective fusion of autophagosomes and lysosomes [21]. The gene discussed is BCL2L1; the disease is neoplasm.